Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide

• Verfasst von: Beier, Fabian [VerfasserIn]
• Verfasst von: Nolte, Florian [VerfasserIn]
• Verfasst von: Hofmann, Wolf-Karsten [VerfasserIn]
• Titel: Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
• Verf.angabe: Fabian Beier, Behzad Kharabi Masouleh, Guntram Buesche, Monica S. Ventura Ferreira, Rebekka K. Schneider, Patrick Ziegler, Stefan Wilop, Lucia Vankann, Norbert Gattermann, Uwe Platzbecker, Aristoteles Giagounidis, Katharina S. Götze, Florian Nolte, Wolf-Karsten Hofmann, Detlef Haase, Hans Kreipe, Jens Panse, Maria A. Blasco, Ulrich Germing, Tim H. Brümmendorf
• E-Jahr: 2015
• Jahr: November 2015
• Umfang: 7 S.
• Fussnoten: Gesehen am 14.12.2017
• Titel Quelle: Enthalten in: Leukemia research
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1977
• Jahr Quelle: 2015
• Band/Heft Quelle: 39(2015), 11, Seite 1292-1298
• ISSN Quelle: 1873-5835
• DOI: doi:10.1016/j.leukres.2015.09.003
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Del (5q)
• Sach-SW: Leukemic stem cell
• Sach-SW: Myelodysplastic syndromes
• Sach-SW: Telomere
• K10plus-PPN: 1566384702

Abstract

Myelodysplastic syndrome (MDS) associated with an acquired, isolated deletion of chromosome 5q (del (5q) MDS), represent a clonal disorder of hematopoiesis and a clinically distinct entity of MDS. Treatment of del (5q) MDS with the drug lenalidomide has significantly improved quality of life leading to transfusion independence and complete cytogenetic response rates (CCR) in the majority of patients. Telomeres are located at the end of eukaryotic chromosomes and are linked to replicative history/potential as well as genetic (in) stability of hematopoietic stem cells. Here, we analyzed telomere length (TL) dynamics before and under lenalidomide treatment in the peripheral blood and/or bone marrow of del (5q) patients enrolled in the LEMON-5 study (NCT01081431). Hematopoietic cells from del (5q) MDS patients were characterized by significantly shortened TL compared to age-matched healthy controls. Telomere loss was more accelerated in patients with longer disease duration (>2 years) and more pronounced cytopenias. Sequential analysis under lenalidomide treatment revealed that previously shortened TL in peripheral blood cells was significantly “elongated” towards normal levels within the first six months suggesting a shift from clonal del (5q) cells towards normal hematopoiesis in lenalidomide treated MDS patients. Taken together our findings suggest that the development of the del (5q) clone is associated with accelerated telomere shortening at diagnosis. However, upon induction of CCR and reoccurrence of normal hematopoiesis, the lack of a persistent TL deficit argues against telomere-mediated genetic instability neither as a disease-promoting event of del (5q) MDS nor for lenalidomide mediated development of secondary primary malignancies of the hematopoietic system in responding patients.